Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.877 USD | +3.87% | +3.68% | +5.39% |
05:15pm | Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment | MT |
May. 09 | Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.39% | 23.01M | |
+43.53% | 50.93B | |
-0.51% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.43% | 26.02B | |
-21.93% | 18.9B | |
+7.68% | 13.21B | |
+24.07% | 12.17B | |
+30.15% | 12.16B |
- Stock Market
- Equities
- LSTA Stock
- News Lisata Therapeutics, Inc.
- Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer